Bottom line
HIBL vs PILL: the short answer
HIBL (Direxion Daily S&P 500(R) High Beta Bull 3X ETF) and PILL (Direxion Daily Pharmaceutical & Medical Bull 3X ETF) share a meaningful slice of their top holdings — about 40% by weight.
Both charge the same expense ratio (0.98%).
Over five years, HIBL returned +16.0% a year vs −12.6% for PILL.
Updated Nov 19, 2026
HIBL vs PILL side by side
| HIBL | PILL | |
|---|---|---|
| Type | ETF | ETF |
| Fund family | Direxion | Direxion |
| Category | Leveraged & Inverse | Leveraged & Inverse |
| Expense ratio | 0.98% | 0.98% |
| Annual cost per $10k | $98 | $98 |
| 10-yr cost on $10k (prospectus) | $1,234 | $1,456 |
| Max front load | None | None |
| 12b-1 fee | 0% | 0% |
| 1-yr return | +60.4% | +75.0% |
| 5-yr return (annualized) | +16.0% | −12.6% |
| 10-yr return (annualized) | — | — |
| Best quarter | +131.6% | +103.7% |
| Worst quarter | −84.1% | −61.4% |
| Net assets (fund) | $75.0M | $20.7M |
| Number of holdings | 108 | 73 |
| Portfolio turnover | 165% | 88% |
| Returns as of | Dec 31, 2025 | Dec 31, 2025 |
Source: SEC Form N-PORT and fund prospectuses
Year-by-year returns
| Year | HIBL | PILL | Difference |
|---|---|---|---|
| 2025 | +60.4% | +75.0% | −14.6% |
| 2024 | −0.8% | −6.9% | +6.1% |
| 2023 | +81.4% | −12.7% | +94.0% |
| 2022 | −68.2% | −43.1% | −25.1% |
| 2021 | +129.0% | −37.2% | +166.1% |
| 2020 | −25.1% | −0.3% | −24.7% |
Source: Fund prospectus bar charts
Holdings overlap
6 of HIBL's top 25 holdings also appear in PILL's top 25.
| Holding | HIBL | PILL |
|---|---|---|
| Goldman Financial | 27.01% | 22.36% |
| Dreyfus | 8.00% | 8.14% |
| N/a | 7.15% | 7.41% |
| N/a | 4.73% | 7.41% |
| N/a | 3.14% | 7.41% |
| Goldman Sachs Liq Es Fd A | 1.01% | 2.03% |
Source: SEC Form N-PORT
HIBL top 10
- Goldman Financial — 27.01%
- Dreyfus — 8.00%
- N/a — 7.15%
- N/a — 4.73%
- N/a — 3.14%
- Robinhood Markets Inc — 1.27%
- Micron Technology Inc — 1.16%
- Sandisk Corp — 1.12%
- Dell Technologies Inc — 1.08%
- United Airlines Holdings Inc — 1.04%
PILL top 10
- Goldman Financial — 22.36%
- N/a — 16.36%
- Dreyfus — 8.14%
- N/a — 7.41%
- Crinetics Pharmaceuticals In — 2.77%
- Mbx Biosciences Inc — 2.42%
- Ataibeckley Inc — 2.16%
- Definium Therapeutics, Inc — 2.13%
- Goldman Sachs Liq Es Fd A — 2.03%
- Amylyx Pharmaceuticals Inc — 1.72%
FAQ
What is the difference between HIBL and PILL?
Which is cheaper, HIBL or PILL?
Should I own both HIBL and PILL?
Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.